Chiasma is a biopharmaceutical company dedicated to improving the lives of patients with rare diseases by developing and commercializing oral medications that were previously available by injection only. The company's lead candidate is octreotide capsules, which has received orphan drug designation from the FDA and EMA. Chiasma is evaluating additional proteins, peptides and small molecule drugs that that are currently only available by injection but could potentially be converted to oral delivery using the company's TPE technology.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 03/02/15 | $70,000,000 | Series E |
7 Med Health Ventures Abingworth ARCH Venture Partners F2 Capital MPM Capital Rock Springs Capital Sofinnova Ventures | undisclosed |
